Per Svenningsson

List of Publications by Year
in descending order

228 papers	10,872 citations	53794 45 h-index	39675 94 g-index
234 all docs	234 docs citations	234 times ranked	14006 citing authors

#	Article	IF	Citations
1	DARPP-32: An Integrator of Neurotransmission. Annual Review of Pharmacology and Toxicology, 2004, 44, 269-296.	9.4	639
2	Adenosine and Brain Function. International Review of Neurobiology, 2005, 63, 191-270.	2.0	601
3	Alterations in 5-HT1B Receptor Function by p11 in Depression-Like States. Science, 2006, 311, 77-80.	12.6	507
4	Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature, 2001, 410, 376-380.	27.8	442
5	Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurology, The, 2012, 11, 697-707.	10.2	432
6	Vagotomy and Parkinson disease. Neurology, 2017, 88, 1996-2002.	1.1	324
7	Diverse Psychotomimetics Act Through a Common Signaling Pathway. Science, 2003, 302, 1412-1415.	12.6	306
8	Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. Nature Genetics, 2015, 47, 579-581.	21.4	237
9	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	12.8	219
10	Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3182-3187.	7.1	217
11	How can drug discovery for psychiatric disorders be improved?. Nature Reviews Drug Discovery, 2007, 6, 189-201.	46.4	217
12	Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study. , 1997, 27, 322-335.		206
13	Direct Targeted Quantitative Molecular Imaging of Neurotransmitters in Brain Tissue Sections. Neuron, 2014, 84, 697-707.	8.1	188
14	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinsonâ€™s disease. Brain, 2015, 138, 2687-2700.	7.6	168
15	Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology, 2014, 82, 2017-2025.	1.1	158
16	DARPP-32 mediates the actions of multiple drugs of abuse. AAPS Journal, 2005, 7, E353-E360.	4.4	152
17	Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6 Receptor Stimulation. Journal of Neuroscience, 2007, 27, 4201-4209.	3.6	149
18	Role of p11 in Cellular and Behavioral Effects of 5-HT4 Receptor Stimulation. Journal of Neuroscience, 2009, 29, 1937-1946.	3.6	149

#	Article	IF	Citations
19	Comprehensive mapping of neurotransmitter networks by MALDIâ€“MS imaging. Nature Methods, 2019, 16, 1021-1028.	19.0	148
20	p11 and its role in depression and therapeutic responses to antidepressants. Nature Reviews Neuroscience, 2013, 14, 673-680.	10.2	144
21	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	10.1	144
22	Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinsonâ€™s disease: a dose-finding study. Brain, 2015, 138, 963-973.	7.6	140
23	Dopamine D1Receptor-mediated Facilitation of GABAergic Neurotransmission in the Rat Strioentopeduncular Pathway and its Modulation by Adenosine A1Receptor-mediated Mechanisms. European Journal of Neuroscience, 1996, 8, 1545-1553.	2.6	134
24	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews Neurology, 2020, 16, 265-284.	10.1	121
25	Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. European Journal of Neuroscience, 2007, 26, 3509-3517.	2.6	116
26	DARPP-32 mediates serotonergic neurotransmission in the forebrain. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3188-3193.	7.1	114
27	Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. International Journal of Neuropsychopharmacology, 2012, 15, 669-679.	2.1	114
28	p11 (S100A10) â€" an inducible adaptor protein that modulates neuronal functions. Current Opinion in Pharmacology, 2007, 7, 27-32.	3.5	112
29	Reversal of Depressed Behaviors in Mice by p11 Gene Therapy in the Nucleus Accumbens. Science Translational Medicine, 2010, 2, 54ra76.	12.4	105
30	Absence of the Autophagy Adaptor SQSTM1/p62 Causes Childhood-Onset Neurodegeneration with Ataxia, Dystonia, and Gaze Palsy. American Journal of Human Genetics, 2016, 99, 735-743.	6.2	99
31	A Role for p11 in the Antidepressant Action of Brain-Derived Neurotrophic Factor. Biological Psychiatry, 2010, 68, 528-535.	1.3	83
32	Genetic Deletion of Trace Amine 1 Receptors Reveals Their Role in Auto-Inhibiting the Actions of Ecstasy (MDMA). Journal of Neuroscience, 2011, 31, 16928-16940.	3.6	80
33	Mass Spectrometry Imaging, an Emerging Technology in Neuropsychopharmacology. Neuropsychopharmacology, 2014, 39, 34-49.	5.4	79
34	Neurogenic Effects of Fluoxetine Are Attenuated in p11 (S100A10) Knockout Mice. Biological Psychiatry, 2010, 67, 1048-1056.	1.3	78
35	Quantitative susceptibility mapping differentiates between parkinsonian disorders. Parkinsonism and Related Disorders, 2017, 44, 51-57.	2.2	77
36	Epigenetics and energetics in ventral hippocampus mediate rapid antidepressant action: Implications for treatment resistance. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7906-7911.	7.1	75

#	Article	IF	Citations
37	Nigrostriatal dopamine transporter availability in early Parkinson's disease. Movement Disorders, 2018, 33, 592-599.	3.9	73
38	Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease. Nature Neuroscience, 2015, 18, 826-835.	14.8	72
39	Simultaneous imaging of multiple neurotransmitters and neuroactive substances in the brain by desorption electrospray ionization mass spectrometry. NeuroImage, 2016, 136, 129-138.	4.2	68
40	CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. Proteomics - Clinical Applications, 2016, 10, 1242-1253.	1.6	64
41	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Journal of Neurochemistry, 2016, 139, 290-317.	3.9	58
42	Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study. Movement Disorders, 2016, 31, 1422-1423.	3.9	56
43	Binding of Î±-synuclein oligomers to Cx32 facilitates protein uptake and transfer in neurons and oligodendrocytes. Acta Neuropathologica, 2019, 138, 23-47.	7.7	56
44	Genome-wide Association Analysis of Parkinsonâ€™s Disease and Schizophrenia Reveals Shared Genetic Architecture and Identifies Novel Risk Loci. Biological Psychiatry, 2021, 89, 227-235.	1.3	53
45	Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden. Neurobiology of Aging, 2016, 45, 212.e5-212.e11.	3.1	50
46	PET imaging of [11C]PBR28 in Parkinsonâ€™s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 367-375.	6.4	50
47	Synaptic proteins in CSF relate to Parkinsonâ€™s disease stage markers. Npj Parkinson's Disease, 2017, 3, 7.	5.3	49
48	NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism. Behavioural Brain Research, 2015, 287, 89-95.	2.2	48
49	Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-Motor Symptoms in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2019, 9, 705-709.	2.8	48
50	Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8765-E8774.	7.1	47
51	Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2Î²-Carbofluoroethoxy-3Î²-(4â€²-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease. Journal of Nuclear Medicine, 2015, 56, 714-720.	5.0	46
52	Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, l-DOPA Responsivity, and Glutamatergic Neurotransmission. Journal of Neuroscience, 2015, 35, 14057-14069.	3.6	46
53	A randomized placebo-controlled PET study of ketamineÂ´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression. Translational Psychiatry, 2020, 10, 159.	4.8	46
54	Dopamine D1/5 receptor stimulation induces c-fosexpression in the subthalamic nucleus: possible involvement of local D5 receptors. European Journal of Neuroscience, 2002, 15, 133-142.	2.6	45

#	Article	IF	Citations
55	Co-expression of serotonin 5-HT1B and 5-HT4 receptors in p11 containing cells in cerebral cortex, hippocampus, caudate-putamen and cerebellum. Neuropharmacology, 2011, 61, 442-450.	4.1	45
56	Increased Expression of NGFI-A mRNA in the Rat Striatum Following Burst Stimulation of the Medial Forebrain Bundle. European Journal of Neuroscience, 1997, 9, 2370-2382.	2.6	44
57	Ketamine decreases neuronally released glutamate via retrograde stimulation of presynaptic adenosine A1 receptors. Molecular Psychiatry, 2021, 26, 7425-7435.	7.9	43
58	Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool. Neuropharmacology, 2018, 143, 38-48.	4.1	40
59	Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinsonâ€™s Disease. Journal of Medicinal Chemistry, 2018, 61, 5269-5278.	6.4	40
60	Î¼- and Î´-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons. European Journal of Neuroscience, 1999, 11, 2182-2186.	2.6	39
61	GPR37 Protein Trafficking to the Plasma Membrane Regulated by Prosaposin and GM1 Gangliosides Promotes Cell Viability. Journal of Biological Chemistry, 2014, 289, 4660-4673.	3.4	39
62	Expanding the ataxia with oculomotor apraxia type 4 phenotype. Neurology: Genetics, 2016, 2, e49.	1.9	37
63	Cellâ€•and regionâ€specific expression of depressionâ€related protein p11 (S100a10) in the brain. Journal of Comparative Neurology, 2017, 525, 955-975.	1.6	37
64	Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy. Neurobiology of Disease, 2020, 137, 104738.	4.4	36
65	Exercise prevents raphe nucleus mitochondrial overactivity in a rat depression model. Physiology and Behavior, 2014, 132, 57-65.	2.1	35
66	Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4726-35.	7.1	35
67	Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2735-2740.	7.1	35
68	Î±-synucleinâ^'lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15226-15235.	7.1	33
69	On the fluxes of side-chain oxidized oxysterols across blood-brain and blood-CSF barriers and origin of these steroids in CSF (Review). Journal of Steroid Biochemistry and Molecular Biology, 2019, 188, 86-89.	2.5	33
70	Evaluation of 3-Ethyl-3-(phenylpiperazinylbutyl)oxindoles as PET Ligands for the Serotonin 5-HT₇ Receptor: Synthesis, Pharmacology, Radiolabeling, and in Vivo Brain Imaging in Pigs. Journal of Medicinal Chemistry, 2015, 58, 3631-3636.	6.4	32
71	S100B interacts with the serotonin 5-HT7 receptor to regulate a depressive-like behavior. European Neuropsychopharmacology, 2015, 25, 2372-2380.	0.7	32
72	SQSTM1/p62-Directed Metabolic Reprogramming Is Essential for Normal Neurodifferentiation. Stem Cell Reports, 2019, 12, 696-711.	4.8	32

#	Article	IF	Citations
73	Modulation of Ion Channels and Receptors by p11 (S100A10). Trends in Pharmacological Sciences, 2020, 41, 487-497.	8.7	32
74	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. Alzheimer's and Dementia, 2020, 16, 292-304.	0.8	29
75	Mass spectrometry imaging identifies abnormally elevated brain <scp>l</scp> -DOPA levels and extrastriatal monoaminergic dysregulation in <scp>l</scp> -DOPAâ€“induced dyskinesia. Science Advances, 2021, 7, .	10.3	29
76	MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration. Nature, 2021, 594, 117-123.	27.8	29
77	Functional <scp>GPR</scp>37 trafficking protects against toxicity induced by 6â€<scp>OHDA</scp>,<scp> MPP</scp>+ or rotenone in a catecholaminergic cell line. Journal of Neurochemistry, 2013, 124, 410-417.	3.9	28
78	5-HT6 receptor agonism facilitates emotional learning. Frontiers in Pharmacology, 2015, 6, 200.	3.5	28
79	Modulation of Monoamine Receptors by Adaptor Proteins and Lipid Rafts: Role in Some Effects of Centrally Acting Drugs and Therapeutic Agents. Annual Review of Pharmacology and Toxicology, 2011, 51, 211-242.	9.4	27
80	Attenuated beta rebound to proprioceptive afferent feedback in Parkinsonâ€™s disease. Scientific Reports, 2019, 9, 2604.	3.3	27
81	Spatial visualization of comprehensive brain neurotransmitter systems and neuroactive substances by selective in situ chemical derivatization mass spectrometry imaging. Nature Protocols, 2021, 16, 3298-3321.	12.0	27
82	MRI Diffusion in Parkinson's Disease: Using the Technique's Inherent Directional Information to Study the Olfactory Bulb and Substantia Nigra. Journal of Parkinson's Disease, 2012, 2, 171-180.	2.8	26
83	Vertical saccades and antisaccades: complementary markers for motor and cognitive impairment in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2019, 5, 11.	5.3	26
84	Reduction of spontaneous cortical beta bursts in Parkinsonâ€™s disease is linked to symptom severity. Brain Communications, 2020, 2, fcaa052.	3.3	26
85	Positron emission tomography imaging of 5-hydroxytryptamine1B receptors in Parkinson's disease. Neurobiology of Aging, 2014, 35, 867-875.	3.1	25
86	A mass spectrometry imaging approach for investigating how drug-drug interactions influence drug blood-brain barrier permeability. NeuroImage, 2018, 172, 808-816.	4.2	25
87	GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinsonâ€™s Disease Patients. Frontiers in Neuroscience, 2019, 13, 697.	2.8	25
88	The EXPANd trial: effects of exercise and exploring neuroplastic changes in people with Parkinsonâ€™s disease: a study protocol for a double-blinded randomized controlled trial. BMC Neurology, 2019, 19, 280.	1.8	25
89	Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid. Journal of Parkinson's Disease, 2016, 6, 307-315.	2.8	24
90	Folding Underlies Bidirectional Role of GPR37/Pael-R in Parkinson Disease. Trends in Pharmacological Sciences, 2017, 38, 749-760.	8.7	24

#	Article	IF	Citations
91	Dynamic lateral organization of opioid receptors (kappa, mu_{wt} and mu_{N40D}) in the plasma membrane at the nanoscale level. Traffic, 2018, 19, 690-709.	2.7	24
92	Fluoxetine Suppresses Glutamate- and GABA-Mediated Neurotransmission by Altering SNARE Complex. International Journal of Molecular Sciences, 2019, 20, 4247.	4.1	24
93	Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease. Movement Disorders, 2021, 36, 1430-1434.	3.9	24
94	Concomitant Medication Usage with <scp>Levodopaâ€Carbidopa</scp> Intestinal Gel: Results from the <scp>COSMOS</scp> Study. Movement Disorders, 2021, 36, 1853-1862.	3.9	24
95	Ependymal cells-CSF flow regulates stress-induced depression. Molecular Psychiatry, 2021, 26, 7308-7315.	7.9	24
96	24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome. Frontiers in Neurology, 2018, 9, 756.	2.4	23
97	Fixation Duration and Pupil Size as Diagnostic Tools in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 865-875.	2.8	23
98	Adenosine (P1) receptor signalling. Drug Development Research, 1996, 39, 262-268.	2.9	22
99	Acute and repeated treatment with l-DOPA increase c-jun expression in the 6-hydroxydopamine-lesioned forebrain of rats and common marmosets. Brain Research, 2002, 955, 8-15.	2.2	22
100	Molecular imaging identifies age-related attenuation of acetylcholine in retrosplenial cortex in response to acetylcholinesterase inhibition. Neuropsychopharmacology, 2019, 44, 2091-2098.	5.4	22
101	Corticobasal degeneration: advances in clinicopathology and biomarkers. Current Opinion in Neurology, 2019, 32, 597-603.	3.6	22
102	Cross-validated Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Quantitation Protocol for a Pharmaceutical Drug and Its Drug-Target Effects in the Brain Using Time-of-Flight and Fourier Transform Ion Cyclotron Resonance Analyzers. Analytical Chemistry, 2020, 92, 14676-14684.	6.5	22
103	Individually Tailored Internet-Based Cognitive-Behavioral Therapy for Daily Functioning in Patients with Parkinsonâ€™s Disease: A Randomized Controlled Trial. Journal of Parkinson's Disease, 2020, 10, 653-664.	2.8	22
104	Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation. PLoS ONE, 2017, 12, e0177036.	2.5	22
105	Neuropharmacology of the adenosine A2A receptors. Drug Development Research, 1996, 39, 450-460.	2.9	21
106	Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using ¹⁸F-FE-PE2I in Healthy Controls and Parkinson Disease Patients. Journal of Nuclear Medicine, 2016, 57, 1529-1534.	5.0	21
107	Overexpression of Î±-synuclein simultaneously increases glutamate NMDA receptor phosphorylation and reduces glucocerebrosidase activity. Neuroscience Letters, 2016, 611, 51-58.	2.1	21
108	Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism. Experimental Neurology, 2017, 292, 11-20.	4.1	21

#	Article	IF	Citations
109	Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients. Blood Cells, Molecules, and Diseases, 2018, 68, 86-92.	1.4	21
110	Novel Treatment Opportunities Against Cognitive Impairment in Parkinsonâ€™s Disease with an Emphasis on Diabetes-Related Pathways. CNS Drugs, 2019, 33, 143-160.	5.9	21
111	Bromopyrylium Derivatization Facilitates Identification by Mass Spectrometry Imaging of Monoamine Neurotransmitters and Small Molecule Neuroactive Compounds. Journal of the American Society for Mass Spectrometry, 2020, 31, 2553-2557.	2.8	21
112	Update on GPCR-based targets for the development of novel antidepressants. Molecular Psychiatry, 2021, , .	7.9	21
113	Adenosine receptor signaling in vitro and in vivo. Drug Development Research, 2001, 52, 274-282.	2.9	20
114	Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1423-1428.	7.1	19
115	Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinsonâ€™s Disease with Comorbid Depression versus Patients with Major Depressive Disorder. Frontiers in Psychiatry, 2017, 8, 102.	2.6	19
116	Patients are doing it for themselves: A survey on disease-specific knowledge acquisition among people with Parkinsonâ€™s disease in Sweden. Health Informatics Journal, 2019, 25, 91-105.	2.1	19
117	Ecto-GPR37: a potential biomarker for Parkinsonâ€™s disease. Translational Neurodegeneration, 2021, 10, 8.	8.0	19
118	Multiâ€cohort profiling reveals elevated CSF levels of brainâ€enriched proteins in Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2021, 8, 1456-1470.	3.7	19
119	A Noncanonical Postsynaptic Transport Route for a GPCR Belonging to the Serotonin Receptor Family. Journal of Neuroscience, 2012, 32, 17998-18008.	3.6	18
120	Distribution and levels of 5-HT 1B receptors in anterior cingulate cortex of patients with bipolar disorder, major depressive disorder and schizophrenia â€“ An autoradiography study. European Neuropsychopharmacology, 2017, 27, 504-514.	0.7	18
121	Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. Scientific Reports, 2019, 9, 6079.	3.3	18
122	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [<scp>¹¹C</scp>]<scp>PBR28</scp> and Machine Learning Analysis. Movement Disorders, 2022, 37, 119-129.	3.9	18
123	NMDA receptors are altered in the substantia nigra pars reticulata and their blockade ameliorates motor deficits in experimental parkinsonism. Neuropharmacology, 2020, 174, 108136.	4.1	17
124	Integration of Mass Spectrometry Imaging and Machine Learning Visualizes Region-Specific Age-Induced and Drug-Target Metabolic Perturbations in the Brain. ACS Chemical Neuroscience, 2021, 12, 1811-1823.	3.5	17
125	Antidepressant effects on serotonin 1A/1B receptors in the rat brain using a gene x environment model. Neuroscience Letters, 2014, 559, 163-168.	2.1	16
126	Arylpiperazine agonists of the serotonin 5-HT1A receptor preferentially activate cAMP signaling versus recruitment of Î²-arrestin-2. Bioorganic and Medicinal Chemistry, 2015, 23, 4824-4830.	3.0	16

#	Article	IF	Citations
127	Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with aâ€˜GBAâ€˜mutation. Molecular Genetics and Metabolism, 2019, 126, S117.	1.1	16
128	Cerebrospinal Fluid Levels of Kininogenâ€1 Indicate Early Cognitive Impairment in Parkinson's Disease. Movement Disorders, 2020, 35, 2101-2106.	3.9	16
129	Lurasidone and fluoxetine reduce novelty-induced hypophagia and NMDA receptor subunit and PSD-95 expression in mouse brain. European Neuropsychopharmacology, 2015, 25, 1714-1722.	0.7	15
130	Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinsonâ€™s Disease: A Preliminary Cross-Sectional Study. Journal of Parkinson's Disease, 2017, 7, 619-628.	2.8	15
131	A SLC20A2 gene mutation carrier displaying ataxia and increased levels of cerebrospinal fluid phosphate. Journal of the Neurological Sciences, 2017, 375, 245-247.	0.6	14
132	Safety and tolerability of IRL790 in Parkinsonâ€™s disease with levodopa-induced dyskinesiaâ€”a phase 1b trial. Npj Parkinson's Disease, 2018, 4, 35.	5.3	14
133	Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or Î²-Phenylethylamine. Frontiers in Pharmacology, 2018, 9, 166.	3.5	14
134	Deficits in Motor Performance, Neurotransmitters and Synaptic Plasticity in Elderly and Experimental Parkinsonian Mice Lacking GPR37. Frontiers in Aging Neuroscience, 2020, 12, 84.	3.4	14
135	Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 5606.	4.1	14
136	Ropinirole regulates emotionality and neuronal activity markers in the limbic forebrain. International Journal of Neuropsychopharmacology, 2014, 17, 1981-1993.	2.1	13
137	Novel Features and Abnormal Pattern of Cerebral Glucose Metabolism in Spinocerebellar Ataxia 19. Cerebellum, 2018, 17, 465-476.	2.5	13
138	Novel Imaging Biomarkers for Huntingtonâ€™s Disease and Other Hereditary Choreas. Current Neurology and Neuroscience Reports, 2018, 18, 85.	4.2	13
139	Association and Familial Coaggregation of Idiopathic Dystonia With Psychiatric Outcomes. Movement Disorders, 2020, 35, 2270-2278.	3.9	13
140	Feasibility Aspects of Exploring Exercise-Induced Neuroplasticity in Parkinsonâ€™s Disease: A Pilot Randomized Controlled Trial. Parkinson's Disease, 2020, 2020, 1-12.	1.1	13
141	Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinsonâ€™s disease. EJNMMI Research, 2020, 10, 95.	2.5	13
142	Î±-Synuclein induced toxicity in brain stem serotonin neurons mediated by an AAV vector driven by the tryptophan hydroxylase promoter. Scientific Reports, 2016, 6, 26285.	3.3	12
143	p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1429-1434.	7.1	12
144	Genetic Variations and mRNA Expression of NRF2 in Parkinsonâ€™s Disease. Parkinson's Disease, 2017, 2017, 1-7.	1.1	12

#	Article	IF	Citations
145	Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. Parkinsonism and Related Disorders, 2019, 66, 158-165.	2.2	12
146	P11 deficiency increases stress reactivity along with HPA axis and autonomic hyperresponsiveness. Molecular Psychiatry, 2021, 26, 3253-3265.	7.9	12
147	Automated brainstem volumetry can aid in the diagnostics of parkinsonian disorders. Parkinsonism and Related Disorders, 2020, 79, 18-25.	2.2	12
148	High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinsonâ€™s disease cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2407-2416.	6.4	12
149	A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia. Movement Disorders, 2020, 35, 1046-1054.	3.9	12
150	Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease. Movement Disorders, 2021, 36, 481-491.	3.9	12
151	Structureâ€Guided Design of Gâ€Proteinâ€Coupled Receptor Polypharmacology. Angewandte Chemie - International Edition, 2021, 60, 18022-18030.	13.8	12
152	Behavioural and neuroplastic effects of a double-blind randomised controlled balance exercise trial in people with Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, 12.	5.3	12
153	Increasing involvement of CAPN1 variants in spastic ataxias and phenotype-genotype correlations. Neurogenetics, 2021, 22, 71-79.	1.4	11
154	V374A KCND3 Pathogenic Variant Associated With Paroxysmal Ataxia Exacerbations. Neurology: Genetics, 2021, 7, e546.	1.9	10
155	Parkinsonâ€™s disease with restless legs syndromeâ€”an in vivo corneal confocal microscopy study. Npj Parkinson's Disease, 2021, 7, 4.	5.3	10
156	Does Information from the Parkinson KinetiGraphâ„¢ (PKG) Influence the Neurologistâ€™s Treatment Decisions?â€”An Observational Study in Routine Clinical Care of People with Parkinsonâ€™s Disease. Journal of Personalized Medicine, 2021, 11, 519.	2.5	10
157	The cerebellar phenotype of Charcot-Marie-Tooth neuropathy type 4C. Cerebellum and Ataxias, 2019, 6, 9.	1.9	9
158	SLC1A3 variant associated with hemiplegic migraine and acetazolamide-responsive MRS changes. Neurology: Genetics, 2020, 6, e474.	1.9	9
159	TAAR1-Dependent and -Independent Actions of Tyramine in Interaction With Glutamate Underlie Central Effects of Monoamine Oxidase Inhibition. Biological Psychiatry, 2021, 90, 16-27.	1.3	9
160	Plasma Levels of Brain-Derived Neurotrophic Factor and S100B in Relation to Antidepressant Response to Ketamine. Frontiers in Neuroscience, 2021, 15, 698633.	2.8	9
161	Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease. Neurology, 0, , 10.1212/WNL.0000000000200804.	1.1	9
162	Effects of lithium and aripiprazole on brain stimulation reward and neuroplasticity markers in the limbic forebrain. European Neuropsychopharmacology, 2014, 24, 630-638.	0.7	8

#	Article	IF	Citations
163	Teaching Video Neuro Images : Feeding dystonia in chorea-acanthocytosis. Neurology, 2015, 85, e143-4.	1.1	8
164	Eye movements during reading in Parkinson's disease: A pilot study. Movement Disorders, 2018, 33, 1661-1662.	3.9	8
165	Chorea, psychosis, acanthocytosis, and prolonged survival associated with ELAC2 mutations. Neurology, 2018, 91, 710-712.	1.1	8
166	Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia. Neuropharmacology, 2020, 162, 107829.	4.1	8
167	Simplified quantification of [¹⁸F]FE-PE2I PET in Parkinsonâ€™s disease: Discriminative power, testâ€“retest reliability and longitudinal validity during early peak and late pseudo-equilibrium. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1291-1300.	4.3	8
168	A Novel Duplication in <scp>ATXN2</scp> as Modifier for Spinocerebellar Ataxia 3 (<scp>SCA3</scp>) and <scp>C9ORF72â€ALS</scp>. Movement Disorders, 2021, 36, 508-514.	3.9	8
169	A non-invasive olfactory bulb measure dissociates Parkinsonâ€™s patients from healthy controls and discloses disease duration. Npj Parkinson's Disease, 2021, 7, 75.	5.3	8
170	The pattern of the inferocentral whorl region of the corneal subbasal nerve plexus is altered with age. Ocular Surface, 2021, 22, 204-212.	4.4	8
171	Why target brain adenosine receptors? A historical perspective. Parkinsonism and Related Disorders, 2020, 80, S3-S6.	2.2	8
172	Introduction: Exciting news about A _{2A} receptors. Neurology, 2003, 61, S10-1.	1.1	8
173	Wide-field mosaics of the corneal subbasal nerve plexus in Parkinsonâ€™s disease using in vivo confocal microscopy. Scientific Data, 2021, 8, 306.	5.3	8
174	A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism. Scientific Reports, 2022, 12, 2763.	3.3	8
175	Region-Specific and Age-Dependent Multitarget Effects of Acetylcholinesterase Inhibitor Tacrine on Comprehensive Neurotransmitter Systems. ACS Chemical Biology, 2022, 17, 147-158.	3.4	8
176	Involvement of a c-fos-Dependent Mechanism in Caffeine-Induced Expression of the Preprotachykinin A and Neurotensin/Neuromedin N Genes in Rat Striatum. European Journal of Neuroscience, 1997, 9, 2135-2141.	2.6	7
177	PSP-CBS with Dopamine Deficiency in a Female with a FMR1 Premutation. Cerebellum, 2016, 15, 636-640.	2.5	7
178	Saccadic Impairments in Patients with the Norrbottnian Form of Gaucherâ€™s Disease Type 3. Frontiers in Neurology, 2017, 8, 295.	2.4	7
179	Polyneuropathy in Gaucher disease type 1 and 3 â€“ a descriptive case series. Scientific Reports, 2019, 9, 15358.	3.3	7
180	Variant ataxia-telangiectasia with prominent camptocormia. Parkinsonism and Related Disorders, 2019, 62, 253-255.	2.2	7

#	Article	IF	Citations
181	Associations Between Fluctuations in Daytime Sleepiness and Motor and Nonâ€Motor Symptoms in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 44-50.	1.5	7
182	Repurposing GLP1 agonists for neurodegenerative diseases. International Review of Neurobiology, 2020, 155, 91-112.	2.0	7
183	The Effect of Early Life Stress on Emotional Behaviors in GPR37KO Mice. International Journal of Molecular Sciences, 2022, 23, 410.	4.1	7
184	Reductions of p11 and 5-HT1B Receptor Availability in Limbic Brain Regions in Cocaine Dependence. Biological Psychiatry, 2014, 76, 763-764.	1.3	6
185	Pathological Study of a FMR1 Premutation Carrier With Progressive Supranuclear Palsy. Frontiers in Genetics, 2018, 9, 317.	2.3	6
186	GBA RNAi but not catalytic inhibition of glucocerebrosidase with Conduritol-Î²-epoxide increases levels of total Î±-synuclein in SH-SY5Y cells. Neuroscience Letters, 2019, 706, 217-222.	2.1	6
187	Trace Amine-Associated Receptor 1 Contributes to Diverse Functional Actions of O-Phenyl-Iodotyramine in Mice but Not to the Effects of Monoamine-Based Antidepressants. International Journal of Molecular Sciences, 2021, 22, 8907.	4.1	6
188	Progressive Ataxia with Elevated Alpha-Fetoprotein: Diagnostic Issues and Review of the Literature. Tremor and Other Hyperkinetic Movements, 2019, 9, .	2.0	6
189	Locating the neuronal targets for caffeine. Drug Development Research, 1998, 45, 324-328.	2.9	5
190	MCEE Mutations in an Adult Patient with Parkinsonâ€™s Disease, Dementia, Stroke and Elevated Levels of Methylmalonic Acid. International Journal of Molecular Sciences, 2019, 20, 2631.	4.1	5
191	Pain in persons with mild-moderate Parkinsonâ€™s disease: a cross-sectional study of pain severity and associated factors. International Journal of Rehabilitation Research, 2019, 42, 371-376.	1.3	5
192	Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses. Frontiers in Pharmacology, 2020, 11, 304.	3.5	5
193	Tau Isoform-Driven CBD Pathology Transmission in Oligodendrocytes in Humanized Tau Mice. Frontiers in Neurology, 2020, 11, 589471.	2.4	5
194	Involvement of Scratch2 in GalR1-mediated depression-like behaviors in the rat ventral periaqueductal gray. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e1922586118.	7.1	5
195	Toward Novel [18F]Fluorine-Labeled Radiotracers for the Imaging of Î±-Synuclein Fibrils. Frontiers in Aging Neuroscience, 2022, 14, 830704.	3.4	5
196	Ligandâ€specific differential regulation of 5â€hydroxytryptamine receptors: functional selectivity in serotonergic signaling. Environmental Sciences Europe, 2012, 1, 453-466.	5.5	4
197	Progressive brain calcifications and signs in a family with the L9R mutation in the PDGFB gene. Neurology: Genetics, 2016, 2, e84.	1.9	4
198	First Clinicogenetic Description of Parkinson's Disease Related to GBA Mutation S107L. Movement Disorders Clinical Practice, 2019, 6, 254-258.	1.5	4

#	Article	IF	Citations
199	Cerebrospinal Fluid Proteins Altered in Corticobasal Degeneration. Movement Disorders, 2021, 36, 1278-1280.	3.9	4
200	P11 (S100A10) as a potential predictor of ketamine response in patients with SSRI-resistant depression. Journal of Affective Disorders, 2021, 290, 240-244.	4.1	4
201	Cytosolic GPR37, but not GPR37L1, multimerization and its reversal by Parkin: A live cell imaging study. FASEB Journal, 2021, 35, e22055.	0.5	4
202	Effects of a Novel Psychomotor Stabilizer, IRL790, on Biochemical Measures of Synaptic Markers and Neurotransmission. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 126-133.	2.5	3
203	GM1 Is Cytoprotective in GPR37-Expressing Cells and Downregulates Signaling. International Journal of Molecular Sciences, 2021, 22, 12859.	4.1	3
204	Neural correlates of impaired response inhibition in the antisaccade task in Parkinsonâ€™s disease. Behavioural Brain Research, 2022, 422, 113763.	2.2	3
205	Î±-Synuclein induced cholesterol lowering increases tonic and reduces depolarization-evoked synaptic vesicle recycling and glutamate release. Npj Parkinson's Disease, 2022, 8, .	5.3	3
206	The Importance of Sample Handling in Neuropeptidomics. , 0, , 177-189.		2
207	GLRA1 mutation and long-term follow-up of the first hyperekplexia family. Neurology: Genetics, 2018, 4, e259.	1.9	2
208	Decreased Cerebrospinal Fluid AÎ²42 in Patients with Idiopathic Parkinsonâ€™s Disease and White Matter Lesions. Journal of Parkinson's Disease, 2019, 9, 361-367.	2.8	2
209	Altered CSF levels of monoamines in hereditary spastic paraparesis 10. Neurology: Genetics, 2019, 5, e344.	1.9	2
210	Genetically Targeted Clinical Trials in Parkinsonâ€™s Disease: Learning from the Successes Made in Oncology. Genes, 2021, 12, 1529.	2.4	2
211	Patients with Parkinsonâ€™s disease display a dopamine therapy related negative bias and an enlarged range in emotional responses to facial emotional stimuli.. Neuropsychology, 2017, 31, 605-612.	1.3	2
212	Progressive Ataxia with Elevated Alpha-Fetoprotein: Diagnostic Issues and Review of the Literature. Tremor and Other Hyperkinetic Movements, 2020, 9, .	2.0	2
213	POLG-Associated Ataxia Presenting as a Fragile X Tremor/Ataxia Phenocopy Syndrome. Cerebellum, 2016, 15, 632-635.	2.5	1
214	Editorial: Update on movement disorders. Current Opinion in Neurology, 2019, 32, 564-565.	3.6	1
215	Involuntary movements, vocalizations and cognitive decline. Parkinsonism and Related Disorders, 2020, 79, 135-137.	2.2	1
216	Hyperkinesias and Echolalia in Primary Familial Brain Calcification. Annals of Neurology, 2021, 89, 418-419.	5.3	1

#	Article	IF	Citations
217	Adult-Onset Ataxia With Neuropathy and White Matter Abnormalities Due to a Novel SAMD9L Variant. Neurology: Genetics, 2021, 7, e628.	1.9	1
218	Peptidomics-based Discovery of Endogenous Neuropeptides in the Brain. Journal of Chromatography Library, 2003, 68, 155-167.	0.1	0
219	Strategies for Reliable and Improved Identification of Peptides. , 0, , 139-152.		0
220	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Pet Study Using [¹¹C] PBR28 and Machine Learning Enhanced Analysis. SSRN Electronic Journal, 0, , .	0.4	0
221	Editorial: Update on movement disorders. Current Opinion in Neurology, 2021, 34, 539-540.	3.6	0
222	Structureâ€Guided Design of Gâ€Proteinâ€Coupled Receptor Polypharmacology. Angewandte Chemie, 2021, 133, 18170-18178.	2.0	0
223	Reply to: â€œ<scp>HbA1c</scp> and Motor Outcome in Parkinson's Disease in the <scp>Markâ€PD</scp> Studyâ€• Movement Disorders, 2021, 36, 1993-1993.	3.9	0
224	D02â€…Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in huntingtonâ€™s disease. , 2021, , .		0
225	Basic mechanisms of, and treatment targets for, depressive disorders. , 2020, , 779-788.		0
226	Predominant Spastic Paraparesis Associated With the D178N Mutation in PRNP. Neurology: Genetics, 2021, 7, e636.	1.9	0
227	Paroxysmal Kinesigenic Dyskinesia. Tremor and Other Hyperkinetic Movements, 2017, 7, 529.	2.0	0
228	Are ATXN2 variants modifying our understanding about neural pathogenesis, phenotypes, and diagnostic?. Neural Regeneration Research, 2022, 17, 2445.	3.0	0